IOVA Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own IOVA shares is 388, representing 88.91% of the company's common stock.

INVESCO LTD., in the last quarter, reduced its stake in IOVA by -74.1% restricting it's holding to 216.8 thousand shares of worth nearly $3.21M. PICTET ASSET MANAGEMENT HOLDING SA also lessened -38.24% of the IOVA shares from its portfolio, reducing its holding to 3.25 million shares of worth $47.54M. DIMENSIONAL FUND ADVISORS LP also shunned IOVA shares holding by -18.35% last quarter which brought its holding to 2.87 million shares worth $42.56M.

As per its latest 13F filing, VANGUARD GROUP INC increased its stake in IOVA by 9.22% in the last quarter. The institutional holder raised its holding to 24.92 million shares having worth more than $369.24M. HANDELSBANKEN FONDER AB also added 293% more shares of IOVA to its portfolio, raising its holding to 218.9 thousand shares of worth $3.24M. EAM INVESTORS, LLC also increased its IOVA shares holding by 100% which brought its holding to 213.34 thousand shares worth $3.16M.

The insider with the most stakes in IOVA is Rothbaum Wayne P. , director at the company. Additionally, IOVA stock is highly held by 10 percent owner BRISTOL INVESTMENT FUND LTD and 10 percent owner Ayer Capital Management, LP among others.

Company executives, directors, and other insiders own 0.58% percent of Iovance Biotherapeutics, Inc.'s stock. Within the last six months, there have been 1 transaction(s) in which IOVA insiders have sold stock, totaling 50K shares. Insiders that have sold shares include MAYNARD RYAN D, HILLSBERG SANFORD, and AYER CAPITAL MANAGEMENT, LP.

There have been 0 transaction(s) during the past 6-months in which Iovance Biotherapeutics, Inc. insiders have bought stock, totalling 0 shares

Around 7.5K Iovance Biotherapeutics, Inc. shares are held by insiders, which represents about 0.58% of IOVA stock.

IOVA director, Rothbaum Wayne P. holds the largest portfolio of the company's shares. IOVA shares owned by Rothbaum total nearly 28.07 million.

VANGUARD GROUP INC is the largest institutional owner in IOVA which holds 24.92 million shares worth $369.24M or 9.73% of the total IOVA shares outstanding followed by HANDELSBANKEN FONDER AB with ownership of 218.9 thousand shares representing 0.09% of the IOVA ownership. INVESCO LTD. is the third largest stakeholder with 216.8 thousand shares or 0.08% of the ownership worth more than $3.21M.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the IOVA is concerned, it is a stock which is optionable.

Number of IOVA shares short is 61.31M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 304.78M shares of IOVA are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, IOVA has 225.66M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for IOVA is 10.32.